Benitec Biopharma Ltd ADR (BNTC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Benitec Biopharma Ltd ADR (BNTC) has a cash flow conversion efficiency ratio of -0.020x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.78 Million) by net assets ($187.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BNTC equity to assets ratio to measure how much of total assets are equity-financed.
Benitec Biopharma Ltd ADR - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Benitec Biopharma Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Benitec Biopharma Ltd ADR cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Benitec Biopharma Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Benitec Biopharma Ltd ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Attica Holdings S.A.
AT:ATTICA
|
0.023x |
|
Qurient Co. Ltd
KQ:115180
|
-0.314x |
|
Power Wind Health Industry Incorporated
TW:8462
|
0.239x |
|
Wuhan Ligong Guangke Co Ltd
SHE:300557
|
0.008x |
|
CN EVERBRIGHT WATER HD 1
F:BIU2
|
N/A |
|
Yingde Greatchem Chemicals Co. Ltd. A
SHE:300804
|
N/A |
|
Dalian Thermal Power Co Ltd
SHG:600719
|
0.574x |
|
GMM Pfaudler Limited
NSE:GMMPFAUDLR
|
0.053x |
Annual Cash Flow Conversion Efficiency for Benitec Biopharma Ltd ADR (2013–2025)
The table below shows the annual cash flow conversion efficiency of Benitec Biopharma Ltd ADR from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Benitec Biopharma Ltd ADR stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $97.30 Million | $-23.59 Million | -0.242x | +40.96% |
| 2024-06-30 | $47.25 Million | $-19.40 Million | -0.411x | +99.54% |
| 2023-06-30 | $202.00K | $-18.01 Million | -89.168x | -1516.35% |
| 2022-06-30 | $2.88 Million | $-15.90 Million | -5.517x | -760.26% |
| 2021-06-30 | $20.01 Million | $-12.83 Million | -0.641x | +12.87% |
| 2020-06-30 | $10.24 Million | $-7.54 Million | -0.736x | -354.60% |
| 2019-06-30 | $16.57 Million | $4.79 Million | 0.289x | +146.55% |
| 2018-06-30 | $13.77 Million | $-8.55 Million | -0.621x | -23.59% |
| 2017-06-30 | $16.53 Million | $-8.30 Million | -0.502x | +65.02% |
| 2016-06-30 | $14.07 Million | $-20.21 Million | -1.437x | -171.46% |
| 2015-06-30 | $18.31 Million | $-9.69 Million | -0.529x | -22.75% |
| 2014-06-30 | $22.48 Million | $-9.69 Million | -0.431x | -42.34% |
| 2013-06-30 | $30.61 Million | $-9.27 Million | -0.303x | -- |
About Benitec Biopharma Ltd ADR
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single a… Read more